Allenaâs lead product candidate, reloxaliase, is a first-in-class, oral enzyme therapeutic for the treatment of hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, CKD and other serious kidney diseases. Allenaâs second product candidate, ALLN-346, is in preclinical development for patients with hyperuricemia and moderate to severe CKD. Hyperuricemia, or elevated levels of uric acid in the blood, is commonly associated with gout as well as kidney stones and kidney disorders. Source
No articles found.
Together, a potent new drug and a blood test to guide its use can be a life change...
Together, a potent new drug and a blood test to...
We are a leading science and technology company that delivers life-transforming me...
We are a leading science and technology company...
Tivity Health, IncÂŽ is a leading provider of fitness and health improvement progr...
Tivity Health, IncÂŽ is a leading provider of f...
DelMar Pharmaceuticals is a biopharmaceutical company focused on the development a...
DelMar Pharmaceuticals is a biopharmaceutical c...
Join the National Investor Network and get the latest information with your interests in mind.